JP6845162B2 - ケタミン経皮送達システム - Google Patents

ケタミン経皮送達システム Download PDF

Info

Publication number
JP6845162B2
JP6845162B2 JP2017566151A JP2017566151A JP6845162B2 JP 6845162 B2 JP6845162 B2 JP 6845162B2 JP 2017566151 A JP2017566151 A JP 2017566151A JP 2017566151 A JP2017566151 A JP 2017566151A JP 6845162 B2 JP6845162 B2 JP 6845162B2
Authority
JP
Japan
Prior art keywords
delivery device
transdermal delivery
ketamine
plasma concentration
abuse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017566151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518498A (ja
JP2018518498A5 (enExample
Inventor
フアドン・タン
ホック・エス・タン
マイケル・メイヤーソーン
Original Assignee
シェノックス・ファーマシューティカルズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シェノックス・ファーマシューティカルズ・エルエルシー filed Critical シェノックス・ファーマシューティカルズ・エルエルシー
Publication of JP2018518498A publication Critical patent/JP2018518498A/ja
Publication of JP2018518498A5 publication Critical patent/JP2018518498A5/ja
Application granted granted Critical
Publication of JP6845162B2 publication Critical patent/JP6845162B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017566151A 2015-06-27 2016-06-27 ケタミン経皮送達システム Active JP6845162B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185573P 2015-06-27 2015-06-27
US62/185,573 2015-06-27
PCT/US2016/039601 WO2017003935A1 (en) 2015-06-27 2016-06-27 Ketamine transdermal delivery system

Publications (3)

Publication Number Publication Date
JP2018518498A JP2018518498A (ja) 2018-07-12
JP2018518498A5 JP2018518498A5 (enExample) 2019-08-08
JP6845162B2 true JP6845162B2 (ja) 2021-03-17

Family

ID=57609546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566151A Active JP6845162B2 (ja) 2015-06-27 2016-06-27 ケタミン経皮送達システム

Country Status (9)

Country Link
US (2) US11191734B2 (enExample)
EP (1) EP3297620A4 (enExample)
JP (1) JP6845162B2 (enExample)
KR (1) KR102299359B1 (enExample)
CN (1) CN107847469A (enExample)
AU (1) AU2016288188B2 (enExample)
CA (1) CA2987909C (enExample)
HK (1) HK1248578A1 (enExample)
WO (1) WO2017003935A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
JP2020500220A (ja) 2016-11-15 2020-01-09 クラリア ファーマ ホールディング エービー 医薬製剤
AU2018254506A1 (en) * 2017-04-20 2019-10-31 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine
KR20180121352A (ko) 2017-04-28 2018-11-07 닛토덴코 가부시키가이샤 경피 흡수형 제제
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN107823195A (zh) * 2017-11-24 2018-03-23 无锡市精神卫生中心 R‑氯胺酮在抑郁症急性期治疗中的应用
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
CA3097189A1 (en) * 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
US20210308040A1 (en) * 2018-10-26 2021-10-07 Guangzhou Dazhou Biomedicine Ltd. Ketamine oral transmucosal delivery system
CN111346073B (zh) * 2018-12-21 2022-06-10 宜昌人福药业有限责任公司 一种透皮给药的药物组合物及其制备方法和应用
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
EP3725306A1 (en) 2019-04-17 2020-10-21 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system
US11752114B2 (en) 2019-04-17 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
JP7453994B2 (ja) * 2019-04-17 2024-03-21 エルテーエス ローマン テラピー－ジステーメ アーゲー 経皮治療システム
CN109966272A (zh) * 2019-04-30 2019-07-05 深圳市泛谷药业股份有限公司 一种氯胺酮透皮贴剂及其制备方法
GB201912505D0 (en) * 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2021121366A1 (en) 2019-12-20 2021-06-24 Alar Pharmaceuticals Inc. Long-acting injectable formulations of ketamine pamoate salts
WO2021255522A1 (en) * 2020-06-19 2021-12-23 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts
CN117797131A (zh) * 2022-09-30 2024-04-02 宜昌人福药业有限责任公司 S-氯胺酮经皮组合物及其制备方法和应用
WO2024067731A1 (zh) * 2022-09-30 2024-04-04 宜昌人福药业有限责任公司 S-氯胺酮经皮组合物及其制备方法和应用
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression
WO2025037252A1 (en) * 2023-08-14 2025-02-20 Javitt Daniel C Compositions and methods for treatment of chronic pain and depression

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
CA2230690C (en) * 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
ES2357808T3 (es) 2001-06-07 2011-04-29 Christine Dr. Sang Tratamiento del dolor neuropático con antagonistas del receptor de n-metil-d-aspartato (nmda).
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004045601A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
US8741332B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20060205789A1 (en) 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CA2685344A1 (en) 2007-04-26 2008-11-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
BRPI0812368A2 (pt) * 2007-06-08 2015-02-03 Samyang Corp Sistemas de liberação de droga transdérmica do tipo matriz e respectivo método de preparação.
WO2010005507A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
CN102223791A (zh) 2008-09-27 2011-10-19 塔阿克斯有限公司 用于神经病变治疗的局部用制剂
US8394759B2 (en) * 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes
JP2010229045A (ja) * 2009-03-26 2010-10-14 Mikasa Seiyaku Co Ltd 経皮吸収型製剤
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
US9724315B2 (en) * 2011-09-30 2017-08-08 Cmpd Licensing, Llc Compounded transdermal pain management
JP6296985B2 (ja) 2011-10-14 2018-03-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
CN104114714A (zh) 2011-12-14 2014-10-22 阿斯利康(瑞典)有限公司 Gabr-a2诊断
PL2809307T3 (pl) * 2012-01-31 2018-06-29 Grünenthal GmbH Plaster farmaceutyczny do podawania przezskórnego (1r,4r)-6'-fluoro-N,N-dimetylo-4-fenylo-4',9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4-b]indolo]-4-aminy
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
US20130236573A1 (en) 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
SG11201501292UA (en) 2012-08-23 2015-05-28 Stuart L Weg Anxiolytic composition, formulation and method of use
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
MX2015004362A (es) 2012-10-08 2015-12-08 Auckland Uniservices Ltd Derivados de ketamina.
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
EP2983787B1 (en) 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
EP3960162A1 (en) 2013-08-26 2022-03-02 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
CA2923064C (en) * 2014-02-20 2016-10-25 Cura Health Inc. Transdermal composition for treating pain
US11207316B2 (en) 2014-05-30 2021-12-28 West Virginia University Ketamine or dextromethorphan formulations and methods of use
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
EP3215147B1 (en) 2014-11-04 2024-02-28 ACADIA Pharmaceuticals Inc. Neuro-attenuating norketamine compounds and methods
EP3240422A1 (en) 2014-12-31 2017-11-08 Icahn School of Medicine at Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
WO2016172672A1 (en) 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2017139382A1 (en) 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
US10034832B2 (en) 2016-02-12 2018-07-31 Synergistic Therapeutics, Llc Sublingual antidepressant lozenge
US20170266319A1 (en) 2016-03-21 2017-09-21 Children's Hospital Medical Center Methods and compositions for treating conditions associated with spinal cord injury
JP2019512528A (ja) 2016-03-25 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法
US10919842B2 (en) 2016-03-25 2021-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine
US20200297621A1 (en) 2016-04-01 2020-09-24 Good Pharmaceutical Development Company, Llc Topical Compositions for Neuropathic Pain
CN108884019A (zh) 2016-04-11 2018-11-23 克雷西奥生物科技有限公司 氘代氯胺酮衍生物
US20170348252A1 (en) 2016-04-21 2017-12-07 Robert Kent Preparation and Use of Ketamine Derivatives and Ketamine Modifiers in the Treatment of Pain
WO2017205666A1 (en) 2016-05-25 2017-11-30 National Health Research Institutes Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
US20190380978A1 (en) 2016-06-03 2019-12-19 Small Pharma Ltd Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
AU2018254506A1 (en) 2017-04-20 2019-10-31 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine

Also Published As

Publication number Publication date
US20180353437A1 (en) 2018-12-13
EP3297620A4 (en) 2019-01-09
JP2018518498A (ja) 2018-07-12
CA2987909A1 (en) 2017-01-05
KR20180021127A (ko) 2018-02-28
CN107847469A (zh) 2018-03-27
EP3297620A1 (en) 2018-03-28
HK1248578A1 (zh) 2018-10-19
AU2016288188B2 (en) 2021-08-05
AU2016288188A1 (en) 2018-01-04
US20220193000A1 (en) 2022-06-23
US11191734B2 (en) 2021-12-07
KR102299359B1 (ko) 2021-09-07
CA2987909C (en) 2022-04-26
WO2017003935A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
JP6845162B2 (ja) ケタミン経皮送達システム
US20220395469A1 (en) Transdermal drug delivery system for ketamine
JP6212104B2 (ja) オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤
RU2408368C2 (ru) Препараты соли бупропиона с модифицированным высвобождением
JP2023022245A (ja) アセナピンを含有する経皮治療システム
JP5073124B2 (ja) ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤
JP2019501215A (ja) 局所皮膜形成スプレー
CN103432104B (zh) 一种含有普拉克索的透皮贴剂
JPWO2005115355A1 (ja) 貼付製剤
US20210308040A1 (en) Ketamine oral transmucosal delivery system
JP2022087276A (ja) メマンチン経皮送達システム
CN103068377A (zh) 透皮施用美金刚
CN1209108C (zh) 一种经皮肤传递的止吐剂成份和含相同成份的制剂
JPWO2021202329A5 (enExample)
CN113613637B (zh) 含有阿戈美拉汀的经皮治疗系统
Jyothika et al. Types of transdermal drug delivery systems: A literature report of the past decade
JP2010006761A (ja) フェンタニルまたはその塩を含有する経皮吸収型貼付剤およびその製造方法
KR102699924B1 (ko) 프라미펙솔 경피 전달 시스템 및 그 사용
JP7352283B2 (ja) クエン酸フェンタニル含有経皮吸収製剤
HK40025664A (en) Transdermal drug delivery system for ketamine
TWI757253B (zh) 普拉克索經皮貼片系統與用法
KR101964295B1 (ko) 피부 자극이 감소된 메만틴 경피전달 시스템

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210225

R150 Certificate of patent or registration of utility model

Ref document number: 6845162

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250